Eli Lilly’s orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight the company’s growth strength.
Latest Ratings for LLY
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Morgan Stanley | Maintains | Overweight | |
| Feb 2022 | Mizuho | Maintains | Buy | |
| Jan 2022 | Morgan Stanley | Maintains | Overweight |
